NCT01641250View on ClinicalTrials.gov

A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Myelogenous Leukemia, Acute
Interventions
DRUG

RO5429083

Multiple escalating doses

DRUG

cytarabine

1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles

Trial Locations (8)

13273

Marseille

20246

Hamburg

31059

Toulouse

40138

Bologna

44093

Nantes

52074

Aachen

75475

Paris

89081

Ulm

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01641250 - A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter